Gut Microbiota in Cancer Immune Response and Immunotherapy

Zhou, Chenghua; Zhou, Yilu; Fang, Jing‐Yuan

doi:10.1016/j.trecan.2021.01.010

Cited by 145 publications

(86 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Next, as therapeutic response biomarkers, the microbiota can surprisingly determine a patient's likelihood of responding to treatment [45]. Bourgeoning evidence suggests how clinical antibiotics is a predictor of poor survival in various cancers (with some exceptions [14,46]) and might undermine cancer therapies [47].…”

Section: The Microbiota Provides Distinct Biomarkers In Oncologymentioning

confidence: 99%

Redrawing therapeutic boundaries: microbiota and cancer

et al. 2022

View full text Add to dashboard Cite

The unexpected roles of the microbiota in cancer challenge explanations of carcinogenesis that focus on tumor-intrinsic properties. Most tumors contain bacteria and viruses, and the host's proximal and distal microbiota influence both cancer incidence and therapeutic responsiveness. Continuing the history of cancer-microbe research, these findings raise a key question: to what extent is the microbiota relevant for clinical oncology? We approach this by critically evaluating three issues: how the microbiota provides a predictive biomarker of cancer growth and therapeutic responsiveness, the microbiota's causal role(s) in cancer development, and how therapeutic manipulations of the microbiota improve patient outcomes in cancer. Clarifying the conceptual and empirical aspects of the cancer-associated microbiota can orient future research and guide its implementation in clinical oncology.

show abstract

Section: The Microbiota Provides Distinct Biomarkers In Oncologymentioning

confidence: 99%

Redrawing therapeutic boundaries: microbiota and cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Aberrant inflammation is considered as one of the hallmarks of cancer. During the development of CRC, tumor-promoting inflammation induced by gut microbiota usually involves the first two, characterized by the exaggerated production of cytokines by resident innate immune cells and the establishment of an immunosuppressive TME (45)(46)(47). These proinflammatory mediators interact with epithelia to compromise barrier function and further amplify the response by recruiting and activating additional immune cells.…”

Section: Interaction Of Gut Microbiota Metabolites and Crcmentioning

confidence: 99%

Gut Microbiota-Derived Metabolites in Colorectal Cancer: The Bad and the Challenges

Zhang

Qin

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Accumulating evidence from studies in humans and animal models has elucidated that gut microbiota, acting as a complex ecosystem, contributes critically to colorectal cancer (CRC). The potential mechanisms often reported emphasize the vital role of carcinogenic activities of specific pathogens, but in fact, a series of metabolites produced from exogenous dietary substrates or endogenous host compounds occupy a decisive position similarly. Detrimental gut microbiota-derived metabolites such as trimethylamine-N-oxide, secondary bile acids, hydrogen sulfide and N-nitroso compounds could reconstruct the ecological composition and metabolic activity of intestinal microorganisms and formulate a microenvironment that opens susceptibility to carcinogenic stimuli. They are implicated in the occurrence, progression and metastasis of CRC through different mechanisms, including inducing inflammation and DNA damage, activating tumorigenic signaling pathways and regulating tumor immunity. In this review, we mainly summarized the intimate relationship between detrimental gut microbiota-derived metabolites and CRC, and updated the current knowledge about detrimental metabolites in CRC pathogenesis. Then, multiple interventions targeting these metabolites for CRC management were critically reviewed, including diet modulation, probiotics/prebiotics, fecal microbiota transplantation, as well as more precise measures such as engineered bacteria, phage therapy and chemopreventive drugs. A better understanding of the interplay between detrimental microbial metabolites and CRC would hold great promise against CRC.

show abstract

“…Gut microbiota plays an important role in the occurrence and progress of tumors, and the immune system is also the dominant force in tumor control [ 22 ]. Studies have shown that the gut microbiota can regulate immune function to play an antitumor effect [ 23 – 29 ].…”

Section: Gut Microbiota and Tumor Immunitymentioning

confidence: 99%

The Role of Gut Microbiota in Tumor Immunotherapy

Bai

et al. 2021

Journal of Immunology Research

View full text Add to dashboard Cite

Tumor immunotherapy is the fourth therapy after surgery, chemotherapy, and radiotherapy. It has made great breakthroughs in the treatment of some epithelial tumors and hematological tumors. However, its adverse reactions are common or even more serious, and the response rate in some solid tumors is not satisfactory. With the maturity of genomics and metabolomics technologies, the effect of intestinal microbiota in tumor development and treatment has gradually been recognized. The microbiota may affect tumor immunity by regulating the host immune system and tumor microenvironment. Some bacteria help fight tumors by activating immunity, while some bacteria mediate immunosuppression to help cancer cells escape from the immune system. More and more studies have revealed that the effects and complications of tumor immunotherapy are related to the composition of the gut microbiota. The composition of the intestinal microbiota that is sensitive to treatment or prone to adverse reactions has certain characteristics. These characteristics may be used as biomarkers to predict the prognosis of immunotherapy and may also be developed as “immune potentiators” to assist immunotherapy. Some clinical and preclinical studies have proved that microbial intervention, including microbial transplantation, can improve the sensitivity of immunotherapy or reduce adverse reactions to a certain extent. With the development of gene editing technology and nanotechnology, the design and development of engineered bacteria that contribute to immunotherapy has become a new research hotspot. Based on the relationship between the intestinal microbiota and immunotherapy, the correct mining of microbial information and the development of reasonable and feasible microbial intervention methods are expected to optimize tumor immunotherapy to a large extent and bring new breakthroughs in tumor treatment.

show abstract

Gut Microbiota in Cancer Immune Response and Immunotherapy

Cited by 145 publications

References 88 publications

Redrawing therapeutic boundaries: microbiota and cancer

Redrawing therapeutic boundaries: microbiota and cancer

Gut Microbiota-Derived Metabolites in Colorectal Cancer: The Bad and the Challenges

The Role of Gut Microbiota in Tumor Immunotherapy

Contact Info

Product

Resources

About